NDAORALCAPSULE, DELAYED REL PELLETS
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
PREVACID (lansoprazole) by Takeda is proton pump inhibitors [moa]. Approved for proton pump inhibitor [epc]. First approved in 1995.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREVACID (lansoprazole) is an oral proton pump inhibitor (PPI) approved in 1995 for acid-related gastrointestinal disorders. It works by suppressing gastric acid production through inhibition of the H+/K+-ATPase pump in parietal cells. The delayed-release capsule formulation ensures optimal absorption in the small intestine.
$11MPart D
LOE ApproachingDeclining
Legacy brand in competitive decline with minimal team expansion; roles focus on maintenance and managed care relationships rather than growth initiatives.
Mechanism of Action
Proton Pump Inhibitors
Pharmacologic Class:
Proton Pump Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Mar 2026
0GERD (Gastroesophageal Reflux Disease)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Started Sep 2025
500 enrolled
GERD (Gastroesophageal Reflux Disease)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
Started Jun 2025
0Pediatric Gastroesophageal Reflux Disease
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
Started May 2023
24 enrolled
Erosive Esophagitis
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Started May 2023
300 enrolled
Coronary Artery Disease
Worked on PREVACID at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.